


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:24Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405138" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405138</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>cmls</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Mol Life Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cell Mol Life Sci</journal-id><journal-id journal-id-type="pmc-domain-id">4579</journal-id><journal-id journal-id-type="pmc-domain">cmls</journal-id><journal-title-group><journal-title>Cellular and Molecular Life Sciences: CMLS</journal-title></journal-title-group><issn pub-type="ppub">1420-682X</issn><issn pub-type="epub">1420-9071</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405138</article-id><article-id pub-id-type="pmcid-ver">PMC12405138.1</article-id><article-id pub-id-type="pmcaid">12405138</article-id><article-id pub-id-type="pmcaiid">12405138</article-id><article-id pub-id-type="pmid">40892088</article-id><article-id pub-id-type="doi">10.1007/s00018-025-05867-7</article-id><article-id pub-id-type="publisher-id">5867</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Modeling of kidney allograft rejection using hiPSC-derived kidney organoids and HLA-mismatched PBMCs: an <italic toggle="yes">in vitro</italic> co-culture system</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lim</surname><given-names initials="SW">Sun Woo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cui</surname><given-names initials="S">Sheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="X">Xianying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Na</surname><given-names initials="DH">Do Hyun</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="H">Hanbi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shin</surname><given-names initials="YJ">Yoo Jin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kang</surname><given-names initials="H">Hyunhye</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oh</surname><given-names initials="EJ">Eun-Jee</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0048-5717</contrib-id><name name-style="western"><surname>Chung</surname><given-names initials="BH">Byung Ha</given-names></name><address><email>chungbh@catholic.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056cn0e37</institution-id><institution-id institution-id-type="GRID">grid.414966.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0647 5752</institution-id><institution>Transplantation Research Center, Seoul St. Mary&#8217;s Hospital, College of Medicine, The Catholic University of Korea, </institution></institution-wrap>Seoul, Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056cn0e37</institution-id><institution-id institution-id-type="GRID">grid.414966.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0647 5752</institution-id><institution>Division of Nephrology, Department of Internal Medicine, </institution><institution>Seoul St. Mary&#8217;s Hospital, College of Medicine, The Catholic University of Korea, </institution></institution-wrap>222 Banpo-daero, Seocho-Gu, Seoul, 06591 South Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056cn0e37</institution-id><institution-id institution-id-type="GRID">grid.414966.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0647 5752</institution-id><institution>Department of Laboratory Medicine, </institution><institution>The Catholic University of Korea, Seoul St. Mary&#8217;s Hospital, </institution></institution-wrap>Seoul, Korea </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>82</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">476796</issue-id><elocation-id>333</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>20</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="18_2025_Article_5867.pdf"/><abstract id="Abs1"><p id="Par1">The aim of this study is to establish an <italic toggle="yes">in vitro</italic> co-culture system to model allograft rejection using kidney organoids system derived from human induced pluripotent stem cells (hiPSCs). We co-cultured kidney organoids derived from wild-type hiPSCs with HLA-mismatched peripheral blood mononuclear cells (PBMCs) from healthy controls (HC) for 24&#160;h. To assess allogeneic rejection modeling, we measured the expression of HLA molecules, (HLA-ABC and HLA-DR), and evaluated cellular damage in the kidney organoids. Additionally, we analyzed the distribution of T cells and their subsets within the co-cultured PBMCs. The immunosuppressive effect of tacrolimus was also evaluated in this co-culture system. Transcriptomic analysis, conducted using RNA sequencing, identified molecules associated with allogeneic rejection. When kidney organoids were co-cultured with alloreactive PBMCs for 24&#160;h, HLA-ABC and HLA-DR expression significantly increased in kidney organoid cells. Additionally, kidney organoids showed reduced cell viability and increased apoptosis compared to syngeneic controls, as assessed by flow cytometry and Annexin V/PI staining. However, treatment with tacrolimus reduced HLA expression in a dose-dependent manner, highlighting the diminished alloimmune responses. Further analysis of PBMC subsets revealed shifts in T helper (TH) and cytotoxic T cell (TC) populations under allogeneic conditions, including increased effector TH and TC cells. Transcriptomic analysis through RNA sequencing identified 256 differentially expressed genes (DEGs), with notable immune-related pathways such as NF-kappa B and TNF signaling involved in allograft rejection. These results provide evidence that a co-culture system with allogeneic kidney organoids and PBMCs can potentially model transplant rejection in vitro.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00018-025-05867-7.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Kidney organoid</kwd><kwd>Kidney transplantation</kwd><kwd>Allograft rejection</kwd><kwd>HiPSC</kwd></kwd-group><funding-group><award-group><funding-source><institution>The National Research Foundation of Korea </institution></funding-source><award-id>NRF-2021R1A2C2005192</award-id><award-id>RS-2023-00209312</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Kidney transplantation is the most effective treatment for end-stage renal disease, offering patients significantly improved quality of life and longevity [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, despite advancements in transplantation operation techniques and immunosuppressive therapies, allograft rejection continues to be a major challenge, adversely affecting both short- and long-term outcomes [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>]. The complex interaction between the donor kidney and the recipient&#8217;s immune system ultimately determines the transplant&#8217;s fate, with allo-immune responses playing a pivotal role in graft recognition and subsequent rejection [<xref ref-type="bibr" rid="CR6">6</xref>]. Thus, it is essential to employ suitable transplant rejection models to elucidate the intricate mechanisms of allograft rejection and to further research in developing effective, stable immunosuppressive agents.</p><p id="Par3">Similar to other kidney diseases, animal or <italic toggle="yes">in vitro</italic> cell models have been employed in transplant rejection research [<xref ref-type="bibr" rid="CR7">7</xref>]. However, these models of transplant rejection exhibit notable limitations. Particularly, unlike other animal models for kidney diseases, the construction of a transplantation model necessitates advanced surgical skills [<xref ref-type="bibr" rid="CR8">8</xref>]. Consequently, large-scale animal allograft rejection model research demands substantial resources, including financial, time, and specialized human resources [<xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, significant differences in immune responses and metabolic pathways necessitate careful interpretation to accurately predict outcomes in humans [<xref ref-type="bibr" rid="CR9">9</xref>]. These factors may result in smaller-scale studies or interruptions in research due to resource limitations. In this context, <italic toggle="yes">in vitro</italic> models that accurately reflect the complex dynamics of allograft rejection are indispensable for uncovering the underlying mechanisms and for developing innovative therapeutic strategies. However, traditional monolayer cell cultures are often inadequate in representing the three-dimensional architecture and cellular interactions typical of the <italic toggle="yes">in vivo</italic> environment [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Therefore, the development of more physiologically pertinent models that can accurately simulate the interactions between donor tissue and recipient immune cells is urgently needed.</p><p id="Par4">Meanwhile, over the past decade, kidney organoids derived from human induced pluripotent stem cells (hiPSCs) have emerged as pioneering <italic toggle="yes">in vitro</italic> models for kidney disease research [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR15">15</xref>]. Compared to traditional animal or <italic toggle="yes">in vitro</italic> 2D culture cell models, kidney organoid systems offer several advantages for kidney disease research, presenting a more effective avenue for studying complex kidney conditions. For example, employing this system can overcome the limitations of animal models, which often diverge from human tissues; moreover, it facilitates the creation of sophisticated 3D human kidney tissues that are not achievable with 2D cell cultures [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>]. Until now, the kidney organoid system has successfully modeled various kidney diseases such as autosomal dominant polycystic kidney disease and Fabry disease nephropathy [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>]. However, <italic toggle="yes">in vitro</italic> modeling of kidney allograft rejection using a hiPSC -derived kidney organoid system has yet to be attempted.</p><p id="Par5">To address this need, we present a robust <italic toggle="yes">in vitro</italic> model designed to investigate kidney transplant rejection. This model utilizes three-dimensional co-culture systems that incorporate kidney organoids derived from hiPSCs and alloreactive peripheral blood mononuclear cells (PBMCs). This model provides a platform for detailed studies on the pathophysiology of allograft rejection within a controlled laboratory environment.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Peripheral blood mononuclear cell isolation</title><p id="Par6">PBMCs were harvested via sterile venipuncture, collected into citrate tubes (ACD; Becton&#8211;Dickinson, Franklin Lakes, NJ, USA), and subsequently purified using Ficoll-density centrifugation as per the manufacturer&#8217;s protocol (Cellgro, Mediatech, Inc., Herndon, VA, USA). Following purification, the cell count and viability of PBMCs were determined using an automated cell counter (ADAM MC; NanoEntek Inc., Hwaseong-si, Gyeonggi-do, South Korea). PBMC were resuspended in 4&#160;&#176;C cryomedia (CryoSTOR&#174; CS10 #100&#8211;1061; STEMCELL Vancouver, Canada) at a concentration of 1&#8201;&#215;&#8201;10<sup>6</sup> cells/ml, and aliquoted in 1&#160;ml per cryotube (43021; SPL Life Sciences, Pocheon-si, Gyeonggi-do, South Korea). The study was approved by Institutional Review Board of Seoul St. Mary&#8217;s Hospital (KC19TISI0901). All subjects provided informed consent for inclusion before they participated in this study. This study was conducted in accordance with the Declaration of Helsinki.</p></sec><sec id="Sec4"><title>Kidney organoids differentiation from hiPSCs and co-culture with PBMC</title><p id="Par7">Healthy control (HC) hiPSCs were generated from PBMCs of a healthy individual and validation process of successful reprogramming into hiPSCs is presented in supplemental method and Fig. <xref rid="MOESM1" ref-type="media">S1</xref>. Wild-type (WT) hiPSCs (WTC-11) and HC hiPSCs were differentiated into kidney organoids following the previously published protocol [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Initially, hiPSCs were plated in mTeSR1 medium (05850; STEMCELL Technologies, Vancouver, Canada) supplemented with 10&#160;&#956;M Y-27632 (1293823; Biogems, Westlake Village, CA, USA) onto 24-well plates pre-coated with 1.25% Corning Matrigel&#174; hESC Qualified Matrix. After 24&#160;h, the medium was replaced with mTeSR1 containing 2.5% Matrigel&#174;. On the fourth day, the medium was switched to Advanced RPMI (1263302; Thermo Fisher Scientific, Grand Island, NY, USA) supplemented with 12&#160;&#181;M CHIR-99021 (STEMCELL Technologies). Approximately 36&#160;h later, the medium was exchanged for Advanced RPMI enhanced with B27 supplement (17504044, Thermo Fisher Scientific). Organoids continued to be cultured in this medium until they were collected on day 21. Regarding the co-culture, kidney organoids from either WT or HC hiPSCs were co-cultured with PBMCs (1&#8201;&#215;&#8201;10<sup>6</sup> cells/1.9 cm<sup>2</sup> in 500 ul RB media) from HC hiPSCs on day 20 of differentiation for 24&#160;h. The following day, both PBMCs and kidney organoids were harvested for further experiments. To ensure reproducibility, all experiments were performed in triplicate.</p></sec><sec id="Sec5"><title>Human leucocyte antigen (HLA) genotyping and haplotype match</title><p id="Par8">HLA typing was conducted at the Histocompatibility Laboratory at Seoul ST Mary&#8217;s Hospital. WT and HC hiPSCs were analyzed for HLA-A*, -B*, -C*, -DRB1*, and &#8211;DQB1* loci using high -resolution next-generation sequencing (NGS) and the specific mismatches at each loci are detailed in Table <xref rid="MOESM1" ref-type="media">S1</xref>. Libraries were prepared according to the manufacturer&#8217;s protocol using the AllType FAST plex NGS 11 Loci Kit (One Lambda, West Hills, CA, USA) and run on the Ion Torrent S5 XL platform (Thermo Fisher Scientific, Waltham, MA, USA). The resulting reads were analyzed with TypeStream Visual software (One Lambda) to establish HLA genotypes based on the IPD-IMGT/HLA database version 3.51.</p><p id="Par9">Haplotype match or HLA-identity in WT-hiPSC and HC hiPSC was evaluated based on HLA -A*, -B*, -C*, -DRB1*, and &#8211;DQB1* typing following standard criteria. The HLA-ID group primarily comprised sibling transplants, whereas the 1 haplotype-mismatched group included both sibling transplants and parent&#8211;child transplants. HLA-DR match in cadaveric RTx was analyzed by interpreting &#8216;blanks&#8217; as indicators of homozygosity and by counting each allele as a separate antigen. For instance, a homozygous DR 1, &#8211; recipient of a homozygous DR 1, &#8211; RTx was identified as a 2 DR match; a homozygous DR 1, &#8211; recipient of a homozygous DR 2, &#8211; donor RTx was categorized as a 0 DR match; a homozygous DR 1, &#8211; recipient of a RTx from a heterozygous donor (DR 1, 2) was acknowledged as a 1 DR match, etc.</p></sec><sec id="Sec6"><title>Flow cytometry</title><p id="Par10">hiPSCs cells were dissociated using TE (15400054; Life Technologies). Subsequent to being washed twice with FACS buffer (phosphate-buffered saline [PBS] containing 1% bovine serum albumin and 10&#160;mM sodium azide), permeabilized for 30&#160;min using flow cytometry fixation and permeabilization solution (554714; BD Biosciences, San Jose, CA, USA), washed with wash buffer, and stained with antibodies listed in the Table <xref rid="MOESM1" ref-type="media">S2</xref>. Cells were analyzed using a FACS Canto II flow cytometer (BD Biosciences). The data were analyzed using FlowJo&#8482; Software v10.10 (Becton, Dickinson &amp; Company, Ashland, OR, USA).</p></sec><sec id="Sec7"><title>Immunofluorescence</title><p id="Par11">Kidney organoids were washed once with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde for 10&#160;min at 4&#160;&#176;C, and blocked in 5% donkey serum in PBS-T (0.3% Triton X-100 in PBS) for 1&#160;h at room temperature (RT). Following this, kidney organoids were incubated with the primary antibodies listed in Table <xref rid="MOESM1" ref-type="media">S3</xref>. Nucleic acid staining was conducted by incubating with 4&#8242;,6-diamidine-2-phenylindole (10236276001, DAPI, 1:5000; Roche, Basel, Switzerland) for 30&#160;min at room temperature. Images were captured using a Zeiss LSM700 confocal microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany).</p></sec><sec id="Sec8"><title>Annexin V and PI assay</title><p id="Par12">Harvested kidney organoids on day 21 after differentiation were dissociated using TE (15400054; Life Technologies), then were incubated with 5&#160;&#956;l of fluorescein isothiocyanate-conjugated annexin V (BD Biosciences) and 2&#160;&#956;l of PI (Propidium Iodide) in 1&#8201;&#215;&#8201;binding buffer (BD Biosciences) for 15&#160;min at RT, in accordance with the manufacturer&#8217;s protocol. The stained cells were subjected to flow cytometry analysis using a FACS Canto II instrument. The results are presented as the percentage of fluorescent cells relative to the total cell count.</p></sec><sec id="Sec9"><title>qRT-PCR</title><p id="Par13">Total RNA was extracted from cells using RNA-Bee (CD-105B; Tel-Test, Friendswood, TX, USA) following the manufacturer&#8217;s instructions. First-strand cDNA using RNA was synthesized and placed onto quantitative real-time PCR (qRT-PCR) using cDNA systhesis kit (DYRT1120; Dyne Bio Inc, Seongnamsi, South Korea). Relative gene level was normalized to GAPDH level using the change-in-threshold method. Primer sequences are shown in Table <xref rid="MOESM1" ref-type="media">S4</xref>.</p></sec><sec id="Sec10"><title>Library preparation and sequencing</title><p id="Par14">For control and test RNAs, library construction was performed using the QuantSeq 3&#8217; mRNA-Seq Library Prep Kit (Lexogen, Inc., Austria), following the manufacturer&#8217;s instructions. Specifically, total RNA samples (500&#160;ng each) were prepared; an oligo-dT primer with an Illumina-compatible sequence at its 5&#8242; end was hybridized to the RNA and reverse transcribed. Post reverse transcription, the RNA template was degraded, and second-strand synthesis was initiated using a random primer that also contained an Illumina-compatible linker sequence at its 5&#8242; end. Subsequently, the double-stranded library was purified using magnetic beads to eliminate all reaction components. The library then underwent amplification to incorporate the full adapter sequences necessary for cluster generation. The final library was purified to remove PCR components. High-throughput sequencing was conducted as single-end 75-bp sequencing on a NextSeq 500 system (Illumina, Inc., USA).</p></sec><sec id="Sec11"><title>Data analysis</title><p id="Par15">QuantSeq 3 mRNA-Seq reads were aligned using Bowtie2 [<xref ref-type="bibr" rid="CR24">24</xref>]. Bowtie2 indices were generated from either the genome assembly sequence or representative transcript sequences for alignment to both the genome and transcriptome. The alignment files were utilized for transcript assembly, estimating abundance, and identifying differential gene expression. Differentially expressed genes (DEGs) were identified based on counts from both unique and multiple alignments using coverage analysis in BEDtools [<xref ref-type="bibr" rid="CR25">25</xref>]. The read count (RC) data were analyzed using the TMM&#8201;+&#8201;CPM normalization method with EdgeR within R (R development Core Team, 2020) on Bioconductor [<xref ref-type="bibr" rid="CR26">26</xref>]. Gene classification was conducted using searches performed in the DAVID (<ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/">http://david.abcc.ncifcrf.gov/</ext-link>) and Medline databases (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/">https://www.ncbi.nlm.nih.gov/</ext-link>).</p></sec><sec id="Sec12"><title>Statistical analyses</title><p id="Par16">Data are presented as the mean&#8201;&#177;&#8201;standard error (SE) of at least three independent experiments. Multiple comparisons between groups were conducted using a one-way analysis of variance with a Bonferroni <italic toggle="yes">post hoc</italic> test, employing Prism software (version 10.2.0 for Windows; GraphPad Software, La Jolla, CA, USA). Statistical significance was established at <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>Three-dimensional co-culture system using kidney organoids and alloreactive PBMC for inducing allogeneic condition</title><p id="Par17">To set up our in vitro kidney transplant rejection model, which we refer to as the allogeneic condition in a culture dish, we initially conducted HLA mismatch scoring for HLA-A, B, C, DRB1, and DQB1 loci in hiPSCs employed in this study. Table <xref rid="MOESM1" ref-type="media">S1</xref> presents the results of high-resolution WT-hiPSC and HC PBMC HLA-typing for both class-I (A, B, C) and class-II (DRB1, DQB1) antigens using NGS technology. We established a co-culture system by combining a kidney organoid derived from WT-hiPSC with HLA-mismatched PBMC from HC for 24&#160;h as described in the experimental workflows (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A). For the syngeneic control group, we established an HC hiPSC line from this HC&#8217;s PBMC using a reprogramming method with episomal vectors (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). Primary humoral alloimmune activation following allogeneic conditions in the co-culture system was assessed by quantifying the induction of HLA molecules, HLA-ABC, and -DR in whole-well cells via flow cytometric analysis. The proportion of HLA-ABC and HLA-DR-positive cells significantly increased in the allogeneic group compared to the syngeneic group (HLA-ABC, 53.2&#8201;&#177;&#8201;0.4% vs. 41.8&#8201;&#177;&#8201;0.7%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group; HLA-DR, 38.8&#8201;&#177;&#8201;0.7% vs. 49.1&#8201;&#177;&#8201;0.4%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group) (Figs.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B-E).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Vitro recapitulation of allogeneic conditions using co-culture with HLA-mismatched PBMCs and kidney organoids. (<bold>A</bold>) Schematic illustration of experimental conditions for allogeneic conditions using HLA-mismatched PBMCs and kidney organoids derived from hiPSCs. Representative flow cytometric dot plots and graphs showing the HLA-ABC&#8201;+&#8201;cells (<bold>B</bold> and <bold>C</bold>) and HLA-DR&#8201;+&#8201;cells (<bold>D</bold> and <bold>E</bold>) of kidney organoids in the syngeneic group and allogeneic group. Data is presented as mean&#8201;&#177;&#8201;SE. #<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="18_2025_5867_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec15"><title>Increased HLA expression in the kidney organoids in the allogeneic condition</title><p id="Par18">Next, we assessed the expression of HLA molecules in the nephron structure, including podocalyxin (PODXL) in glomerular epithelial cells, lotus tetragonolobus lectin (LTL) in the proximal tubules, and e-cadherin (ECAD) in the distal tubules. Immunofluorescence staining and examination with confocal microscopy revealed that immunoreactivity for HLA-ABC and &#8211;DR was elevated in the allogeneic group compared to the syngeneic group (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A and B). Following co-culture with alloreactive PBMC, the kidney organoids disintegrated into single cells. These cells were then stained with a cocktail of antibodies targeting HLA-ABC, -DR, PODXL, LTL, and ECAD for flow cytometric analysis. Flow cytometric dot plots and quantitative graphs demonstrated that the percentages of HLA-ABC, -DR-positive cells containing nephron structure markers were significantly higher in the allogeneic group than in the syngeneic group (PODXL&#8201;+&#8201;HLA-ABC&#8201;+, 20.9&#8201;&#177;&#8201;0.4% vs. 17.3&#8201;&#177;&#8201;0.5%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group; LTL&#8201;+&#8201;HLA-ABC&#8201;+, 9.2&#8201;&#177;&#8201;0.4% vs. 6.0&#8201;&#177;&#8201;0.3%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group; ECAD&#8201;+&#8201;HLA-ABC&#8201;+, 7.7&#8201;&#177;&#8201;0.2% vs. 2.8&#8201;&#177;&#8201;0.1%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group; PODXL&#8201;+&#8201;HLA-DR&#8201;+, 17.8&#8201;&#177;&#8201;0.4% vs. 13.9&#8201;&#177;&#8201;0.4%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group; LTL&#8201;+&#8201;HLA-DR&#8201;+, 3.9&#8201;&#177;&#8201;0.2 vs. 2.8&#8201;&#177;&#8201;0.2%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group; ECAD&#8201;+&#8201;HLA-DR&#8201;+, 6.0&#8201;&#177;&#8201;0.2% vs. 2.0&#8201;&#177;&#8201;0.1%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C-F).<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Expression of HLA-ABC and HLA-DR in the kidney organoids after co-culture with HLA-mismatched PBMC. After co-culturing with PBMC and maturing kidney organoids for 24&#160;h, the kidney organoids were double labeled with antibodies against HLA-ABC or HLA-DR, as well as PODXL, under both the syngeneic condition (<bold>A</bold>) and the allogeneic condition (<bold>B</bold>). Scale bar&#8201;=&#8201;50&#160;&#956;m. Representative flow cytometric dot plots and their quantitative graphs show the HLA-ABC&#8201;+&#8201;cells (<bold>C</bold> and <bold>E</bold>) and HLA-DR&#8201;+&#8201;cells (<bold>D</bold> and <bold>F</bold>) in the nephron markers, PODXL, LTL, and ECAD in the syngeneic group and allogeneic group. PODXL, podocalyxin; LTL, lotus tetragonolobus lectin; ECAD, e-cadherin. Data are presented as mean&#8201;&#177;&#8201;SE. <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="18_2025_5867_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec16"><title>Reduced cell viability of the kidney organoids in the allogeneic condition</title><p id="Par19">We investigated the effects of HLA-mismatched PBMC on the viability of kidney organoid cells in a co-culture system. The viable cells were labeled using a fluorescence fixable viable cell dye. A histogram of cell viability displayed a reduced median value in the allogeneic group at 1633 compared with 2480 in the syngeneic group (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A). The Annexin V and PI assay indicated that early (Annexin V positive, PI negative) and late apoptotic cells (Annexin V and PI positive) were significantly more prevalent in the allogeneic group than in the syngeneic group (Q2, 16.4&#8201;&#177;&#8201;0.5% vs. 7.3&#8201;&#177;&#8201;0.03%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. the syngeneic group; Q3, 18.9&#8201;&#177;&#8201;0.4% vs. 11.9&#8201;&#177;&#8201;2.4%, *P&#8201;&lt;&#8201;0.05 vs. the syngeneic group). Consistent with the result of Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>A, the percentage of live cells (Annexin V and PI negative) was also lower in the allogeneic group compared to the syngeneic group (65.0&#8201;&#177;&#8201;0.4% vs. 75.1&#8201;&#177;&#8201;0.1%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. the syngeneic group).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Effect of cell viability of the kidney organoids after co-culture with HLA-mismatched PBMC and kidney organoids. (<bold>A</bold>) Representative histogram showing cell viability measured by a fixable viable cell dye in syngeneic and allogeneic groups of kidney organoids. (<bold>B</bold>) Flow cytometry analysis of apoptotic cell death induced under allogeneic conditions using annexin V-FITC/PI staining. (<bold>C</bold>-<bold>F</bold>) The gating strategy includes single PI positive (Q1), double positive (Q2), single annexin V positive (Q3), and double negative (Q4). Data are presented as mean&#8201;&#177;&#8201;SE. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="18_2025_5867_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Tacrolimus reduced the HLA expression in a dose -dependent manner</title><p id="Par20">Figure&#160;<xref rid="Fig4" ref-type="fig">4</xref> illustrates the impact of tacrolimus (Tac) treatment on HLA-ABC and -DR expression in kidney organoids under allogeneic conditions. Immunofluorescence staining and confocal microscopy revealed a gradual decrease in the immunoreactivity of HLA-ABC and -DR as the Tac dose was increased (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>A and B). Additionally, flow cytometric dot plots and their quantitative graphs also indicate that Tac treatment significantly reduced the percentage of HLA-ABC and -DR-positive cells across all nephron structure markers - PODXL, LTL, and ECAD- in a Tac dose -dependent manner relative to the group treated with 0&#160;ng/mL of Tac (PODXL&#8201;+&#8201;HLA-ABC&#8201;+, 7.1&#8201;&#177;&#8201;0.9% in the Tac 0&#160;ng/mL, 5.1&#8201;&#177;&#8201;0.2% in the Tac 1&#160;ng/mL, 2.2&#8201;&#177;&#8201;0.04% in the Tac 10&#160;ng/mL, 1.4&#8201;&#177;&#8201;0.04% in the Tac 100&#160;ng/mL; LTL&#8201;+&#8201;HLA-ABC&#8201;+, 4.3&#8201;&#177;&#8201;0.1% in the Tac 0&#160;ng/mL, 4.0&#8201;&#177;&#8201;0.2% in the Tac 1&#160;ng/mL, 3.0&#8201;&#177;&#8201;0.1% in the Tac 10&#160;ng/mL, 1.6&#8201;&#177;&#8201;0.2% in the Tac 100&#160;ng/mL; ECAD&#8201;+&#8201;HLA-ABC&#8201;+, 17.7&#8201;&#177;&#8201;0.4% in the Tac 0&#160;ng/mL, 14.7&#8201;&#177;&#8201;0.5% in the Tac 1&#160;ng/mL, 11.1&#8201;&#177;&#8201;0.3% in the Tac 10&#160;ng/mL, 5.8&#8201;&#177;&#8201;0.5% in the Tac 100&#160;ng/mL; PODXL&#8201;+&#8201;HLA-DR&#8201;+, 14.0&#8201;&#177;&#8201;1.2% in the Tac 0&#160;ng/mL, 11.2&#8201;&#177;&#8201;0.3% in the Tac 1&#160;ng/mL, 6.0&#8201;&#177;&#8201;0.4% in the Tac 10&#160;ng/mL, 3.2&#8201;&#177;&#8201;0.2% in the Tac 100&#160;ng/mL; LTL&#8201;+&#8201;HLA-DR&#8201;+, 13.9&#8201;&#177;&#8201;0.7% in the Tac 0&#160;ng/mL, 10.6&#8201;&#177;&#8201;0.3% in the Tac 1&#160;ng/mL, 7.2&#8201;&#177;&#8201;0.2% in the Tac 10&#160;ng/mL, 3.5&#8201;&#177;&#8201;0.4% in the Tac 100&#160;ng/mL; ECAD&#8201;+&#8201;HLA-DR&#8201;+, 6.5&#8201;&#177;&#8201;0.1% in the Tac 0&#160;ng/mL, 4.7&#8201;&#177;&#8201;0.2% in the Tac 1&#160;ng/mL, 3.4&#8201;&#177;&#8201;0.1% at Tac 10&#160;ng/mL, 1.8&#8201;&#177;&#8201;0.05% in the Tac 100&#160;ng/mL, <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. 0&#160;ng/mL of Tac group; <sup>$</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. 1&#160;ng/mL of Tac group; <sup>&amp;</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. 10&#160;ng/mL of Tac group).<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Effect of tacrolimus on the expression of HLA-ABC and HLA-DR in the kidney organoids after co-culture with HLA-mismatched PBMC. Tacrolimus was administered during the co-culture of PBMC with mature kidney organoids for 24&#160;h. Subsequently, the kidney organoids were double -labeled with antibodies against HLA-ABC (<bold>A</bold>) or HLA-DR (<bold>B</bold>) and PODXL under an allogeneic condition. Scale bars represent 50&#160;&#956;m. Representative flow cytometric dot plots and corresponding quantitative graphs illustrate HLA-ABC&#8201;+&#8201;cells (<bold>C</bold> and <bold>E</bold>) and HLA-DR&#8201;+&#8201;cells (<bold>D</bold> and <bold>F</bold>) among the nephron markers PODXL, LTL, and ECAD in the allogeneic group. Tac, tacrolimus; PODXL, podocalyxin; LTL, lotus tetragonolobus lectin; ECAD, e-cadherin. Data are presented as mean&#8201;&#177;&#8201;SE. <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. 0&#160;ng/mL of Tac group; <sup>$</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. 1&#160;ng/mL of Tac group; <sup>&amp;</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. 10&#160;ng/mL of Tac group</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="18_2025_5867_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec18"><title>Influence on helper and cytotoxic T cell subsets of the PBMC under in vitro allogeneic condition</title><p id="Par21">In this study, we analyzed the distribution of T cells (CD3<sup>+</sup>) and their subsets, i.e., T<sub>H</sub> (CD4<sup>+</sup>) and T<sub>C</sub> (CD8<sup>+</sup>) cells. Based on CD45RO and CCR7 surface expression levels, both T<sub>H</sub> and T<sub>C</sub> cells were further classified into four subsets: na&#239;ve (CD4<sup>+</sup>CD45RO<sup>-</sup>CCR7<sup>+</sup>), central memory (CM; CD4<sup>+</sup>CD45RO<sup>+</sup>CCR7<sup>+</sup>), effector memory (EM; CD4<sup>+</sup>CD45RO<sup>+</sup>CCR7<sup>-</sup>), and effector (CD4<sup>+</sup>CD45RO<sup>-</sup>CCR7<sup>+</sup>) cells. Additional subsets of T<sub>H</sub> cells analyzed included T<sub>H</sub>1 (CD4<sup>+</sup>CXCR3<sup>+</sup>CCR6<sup>-</sup>), T<sub>H</sub>2 (CD4<sup>+</sup>CXCR3<sup>-</sup>CCR6<sup>-</sup>), and T<sub>H</sub>17 (CD4<sup>+</sup>CXCR3<sup>-</sup>CCR6<sup>+</sup>). The gating strategies are depicted in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>A.<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Comparisons of CD3&#8201;+&#8201;T cell subsets of PBMC after co-culturing with HLA-mismatched kidney organoids between the syngeneic and allogeneic groups with or without Tac. (<bold>A</bold>) Gating strategy for T cell subsets. (<bold>B</bold>) Percentage of total T (CD3&#8201;+), T<sub>H</sub> (CD3&#8201;+&#8201;CD4&#8201;+), and T<sub>C</sub> (CD3&#8201;+&#8201;CD8&#8201;+) cells in each group. (<bold>C</bold>) Percentage of T<sub>H</sub> subsets, EM T<sub>H</sub> (CD3&#8201;+&#8201;CD4&#8201;+&#8201;CD45RO&#8201;+&#8201;CCR7-), CM T<sub>H</sub> (CD3&#8201;+&#8201;CD4&#8201;+&#8201;CD45RO&#8201;+&#8201;CCR7&#8201;+), Eff TH (CD3&#8201;+&#8201;CD4&#8201;+&#8201;CD45RO- CCR7-), and Na&#239;ve TH cells (CD3&#8201;+&#8201;CD4&#8201;+&#8201;CD45RO- CCR7&#8201;+) in each group. (<bold>D</bold>) Percentage of T<sub>C</sub> subsets, EM TC (CD3&#8201;+&#8201;CD8&#8201;+&#8201;CD45RO&#8201;+&#8201;CCR7-), CM T<sub>C</sub> (CD3&#8201;+&#8201;CD8&#8201;+&#8201;CD45RO&#8201;+&#8201;CCR7&#8201;+), Eff T<sub>C</sub> (CD3&#8201;+&#8201;CD8&#8201;+&#8201;CD45RO- CCR7-), and Na&#239;ve T<sub>C</sub> (CD3&#8201;+&#8201;CD8&#8201;+&#8201;CD45RO- CCR7&#8201;+) cells. (<bold>E</bold>) Percentage of T<sub>H</sub> subsets, T<sub>H</sub>1 (CD3&#8201;+&#8201;CD4&#8201;+&#8201;CCR6- CXCR3&#8201;+), T<sub>H</sub>2 (CD3&#8201;+&#8201;CD4&#8201;+&#8201;CCR6- CXCR3-), and T<sub>H</sub>17 (CD3&#8201;+&#8201;CD4&#8201;+&#8201;CCR6&#8201;+&#8201;CXCR3-) cells. T<sub>H</sub>, Helper T cells; T<sub>C</sub> cytotoxic T cells; EM, effector memory; CM, central memory; Eff, effector; PBMC, Peripheral blood mononuclear cell; Tac, Tacrolimus Data are presented as mean&#8201;&#177;&#8201;SE. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group, <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. allogeneic group without tacrolimus</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="18_2025_5867_Fig5_HTML.jpg"/></fig></p><p id="Par22">To examine the immunosuppressive effect of tacrolimus, PBMCs were co-cultured with mature kidney organoids under allogeneic conditions for 24&#160;h in the presence or absence of tacrolimus (10 or 100&#160;ng/mL). In Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>B, the frequencies of total T cells, T<sub>H</sub> cells, and T<sub>C</sub> cells were significantly altered in the allogeneic group compared to the syngeneic group, (T cells, 78&#8201;&#177;&#8201;0.2% vs. 81&#8201;&#177;&#8201;0.3%; T<sub>H</sub> cells, 56&#8201;&#177;&#8201;0.4% vs. 55&#8201;&#177;&#8201;0.2%; T<sub>C</sub> cells, 34&#8201;&#177;&#8201;0.4% vs. 35&#8201;&#177;&#8201;0.2%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group) and these changes were attenuated by tacrolimus treatment (T cells, 67&#8201;&#177;&#8201;3.2% and 71&#8201;&#177;&#8201;1.3%; T<sub>H</sub> cells, 54&#8201;&#177;&#8201;0.2% and 47&#8201;&#177;&#8201;1.2%; T<sub>C</sub> cells, 34&#8201;&#177;&#8201;0.3% and 34&#8201;&#177;&#8201;0.3%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. allogeneic group without tacrolimus, allogeneic group&#8201;+&#8201;Tac10 or Tac100, respectively). As shown in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>C, the percentage of effector T<sub>H</sub> cells was significantly elevated in the allogeneic group (51&#8201;&#177;&#8201;0.4% vs. 43&#8201;&#177;&#8201;0.3%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group), while EM and CM T<sub>H</sub> cells were reduced (EM T<sub>H</sub> cells, 25&#8201;&#177;&#8201;0.6% vs. 27&#8201;&#177;&#8201;0.3%; CM T<sub>H</sub> cells, 3.8&#8201;&#177;&#8201;0.1% vs. 5.1&#8201;&#177;&#8201;0.2%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group); these changes were partially reversed by tacrolimus treatment (Eff T<sub>H</sub> cells, 38&#8201;&#177;&#8201;0.4% and 34&#8201;&#177;&#8201;0.3%; EM T<sub>H</sub> cells, 28&#8201;&#177;&#8201;0.5% and 37&#8201;&#177;&#8201;0.9%; CM T<sub>H</sub> cells, 5.4&#8201;&#177;&#8201;0.1% and 6.4&#8201;&#177;&#8201;0.1%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. allogeneic group without tacrolimus, allogeneic group&#8201;+&#8201;Tac10 or Tac100, respectively). Similarly, effector T<sub>C</sub> cells and EM T<sub>C</sub> cells were significantly increased in the allogeneic group (EM T<sub>C</sub> cells, 6.2&#8201;&#177;&#8201;0.2% vs. 4.6&#8201;&#177;&#8201;0.2%; Eff T<sub>C</sub> cells, 17.7&#8201;&#177;&#8201;0.2% vs. 16.2&#8201;&#177;&#8201;0.2%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group), and tacrolimus treatment significantly suppressed the increase in effector T<sub>C</sub> cells (Eff T<sub>C</sub> cells, 16&#8201;&#177;&#8201;0.4% and 15&#8201;&#177;&#8201;0.3%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. allogeneic group without tacrolimus, allogeneic group&#8201;+&#8201;Tac10 or Tac100, respectively) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>D). Furthermore, as shown in Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>E, the proportion of T<sub>H</sub>1 cells was markedly decreased in the allogeneic group and further reduced by tacrolimus treatment. (T<sub>H</sub>1 cells, 10.5&#8201;&#177;&#8201;0.2% vs. 31.2&#8201;&#177;&#8201;0.3%; <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group; 6.9&#8201;&#177;&#8201;0.2% and 5&#8201;&#177;&#8201;0.3%. <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. allogeneic group without tacrolimus, allogeneic group&#8201;+&#8201;Tac10 or Tac100, respectively). In contrast, the proportion of T<sub>H</sub>2 and T<sub>H</sub>17 cells was elevated in the allogeneic group compared to the syngeneic group (T<sub>H</sub>2 cells, 86.5&#8201;&#177;&#8201;0.6% vs. 65.2&#8201;&#177;&#8201;0.3%; T<sub>H</sub>17 cells, 2.7&#8201;&#177;&#8201;0.1% vs. 2.0&#8201;&#177;&#8201;0.1%, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group), and this increase was partially suppressed by tacrolimus at both concentrations (T<sub>H</sub>2 cells, 85&#8201;&#177;&#8201;1.1% and 77&#8201;&#177;&#8201;1.6%; T<sub>H</sub>17 cells, 2.1&#8201;&#177;&#8201;0.1% and 1.8&#8201;&#177;&#8201;0.1%, <sup><italic toggle="yes">#</italic></sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. allogeneic group without tacrolimus, allogeneic group&#8201;+&#8201;Tac10 or Tac100, respectively).</p></sec><sec id="Sec19"><title>Transcriptomic analysis of the kidney organoids derived allogeneic condition versus syngeneic condition</title><p id="Par23">To investigate the differences in gene expression profiles of kidney organoids between syngeneic and allogeneic conditions, we conducted a transcriptomic analysis using RNA-sequencing. The results are illustrated in the hierarchical clustering heat map (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>A), scatter plot (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>B), and volcano plot (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>C), which depict global transcriptomic variations between the groups. A total of 43,424 RNA transcripts were identified in the kidney organoids; moreover, we discovered 256 DEGs with a <italic toggle="yes">p</italic>-value of&#8201;&lt;&#8201;0.05. Among these, 93 genes were two-fold upregulated while 163 genes were two-fold downregulated. Additionally, a bubble or radar chart displays the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, predicting the potential functions of the DEGs (Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>D and E). The NF-&#954;B and TNF&#945; signaling pathways were ranked at the top, suggest that the co-cultivation of kidney organoids with HLA-mismatched PBMCs reflects kidney allograft rejection. Figure&#160;<xref rid="Fig6" ref-type="fig">6</xref> presents the qRT-PCR results for NF-&#954;B, I&#954;B&#945;, TNF&#945;, and IL-6 which play critical roles in the NF-&#954;B and TNF&#945; signaling pathways (NF-&#954;B, 1.35&#8201;&#177;&#8201;0.32; I&#954;B&#945;, 0.60&#8201;&#177;&#8201;0.1; TNF&#945;, 1.22&#8201;&#177;&#8201;0.15; IL-6, 1.83&#8201;&#177;&#8201;0.11, <italic toggle="yes">*P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group).<fig id="Fig6" position="float" orientation="portrait"><label>Fig.&#160;6</label><caption><p>Whole transcriptome analysis of the kidney organoids of allogeneic group versus syngeneic group. (<bold>A</bold>) Heat map and hierarchical clustering of RNA-sequencing data from the kidney organoids of both the syngeneic and allogeneic groups. Scatter plot (<bold>B</bold>) and volcano plot (<bold>C</bold>) illustrate the significant transcriptional changes in genes associated with allogeneic conditions. (<bold>D</bold>) The size and color of each bubble indicate the number of significantly changed genes enriched in the pathway and &#8211;log10 (p-value), respectively. The Y-axis represents the pathway name, and the x-axis represents the fold enrichment factor. (<bold>E</bold>) A radar chart displays normalized enrichment scores for genes with significant transcriptional changes in the allogeneic group across hallmark pathways; pathways more overrepresented in the allogeneic group than in the syngeneic group are highlighted with red brackets. (<bold>F</bold>) qRT-PCR result for mRNA level of NF-&#954;B, I&#954;B&#945;, TNF&#945;, and IL-6 in the kidney organoids. Data are presented as mean&#8201;&#177;&#8201;SE. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 vs. syngeneic group</p></caption><graphic id="MO6" position="float" orientation="portrait" xlink:href="18_2025_5867_Fig6_HTML.jpg"/></fig></p></sec></sec><sec id="Sec20"><title>Discussion</title><p id="Par24">The study presented delineates a robust in vitro model for investigating kidney transplant rejection, utilizing a three-dimensional co-culture system that integrates kidney organoids derived from hiPSCs with alloreactive PBMCs. Through meticulous experimental workflows and comprehensive analyses, this study elucidates the dynamics of allogeneic conditions, highlighting critical aspects such as HLA expression, cell viability, immune cell subsets, and transcriptomic alterations.</p><p id="Par25">Our first aim was to determine whether kidney organoids could be utilized in an allograft rejection model by inducing an immune response. HLA is a crucial component of the human immune system, and increased HLA expression on kidney allograft cells can serve as a marker of immune recognition by the recipient&#8217;s immune system, potentially leading to allograft rejection [<xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref>]. As a preliminary step, we exposed the kidney organoids to the inflammatory cytokine IFN-&#947;, and observing an increase in HLA expression on the surface of kidney organoid constituent cells (Figs. <xref rid="MOESM1" ref-type="media">S2</xref>&#160;and <xref rid="MOESM1" ref-type="media">3</xref>). Subsequently, we assessed whether there was an increase in HLA expression on the surface of the organoid cells to determine if an immune response occurred between the immune cells of PBMC and kidney organoids. The human immune system perceives mismatched HLA as"foreign"and mounts an attack, which primarily manifests as phenomena such as allograft rejection [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. The more mismatched HLA there are, the stronger the immune reaction can be [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, we selected PBMCs and hiPSCs with completely mismatched HLA-class I and II genotyping to develop a co-culture system of PBMC- and hiPSC -derived kidney organoids. As a result, we observed heightened expression of HLA molecules, notably HLA-ABC and HLA-DR, in kidney organoids under allogeneic conditions. Furthermore, the augmentation of HLA expression across different cells constituting nephron structures, such as podocyte, proximal, or distal tubule cells, underscores the pervasive impact of alloreactive PBMCs on kidney organoid physiology.</p><p id="Par26">Next, we investigated whether elevated HLA expression contributed to cell damage, as observed in the real process of allograft rejection. The upregulation of HLA expression on cells is often associated with various physiological and pathological processes, including immune activation, inflammation, and tissue injury [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Inflammatory cytokines or chemokines released in response to HLA-mediated immune activation can recruit immune cells to the site of injury, exacerbating tissue damage through various mechanisms [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. In this study, we also found that concomitant with the upregulation of HLA expression, there was a notable reduction in cell viability within the allogeneic milieu. RNA-seq analysis also revealed that apoptosis-related gene expression profiles showed distinct clustering between allogeneic and syngeneic groups, with pro-apoptotic genes (e.g., XAF1, FAS, PMAIP1) upregulated and survival-related genes (e.g., CD24, RIPK1, PPP1R13L) downregulated in the allogeneic group (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). This decline in cellular viability, coupled with the increased incidence of apoptotic phenomena, highlights the cytotoxic effects exerted by alloreactive PBMCs on kidney organoids. Such observations indicate the harmful effects of allogeneic interactions on the structural integrity and viability of renal tissues.</p><p id="Par27">Furthermore, we have elucidated the immunomodulatory impacts of tacrolimus, an immunosuppressant, on HLA expression and cell viability within the allogeneic context. Tacrolimus exerts its immunosuppressive effect primarily by inhibiting the calcineurin pathway, thereby reducing IL-2 production and T cell activation. This suppression affects the differentiation and proliferation of both CD4<sup>+</sup> helper T cells and CD8<sup>+</sup> cytotoxic T cells, contributing to reduced alloimmune responses [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In addition, Tacrolimus may indirectly influence antigen presentation through downregulation of HLA expression on antigen-presenting cells or target organ cells [<xref ref-type="bibr" rid="CR6">6</xref>]. Consequently, tacrolimus diminishes HLA expression on the surface of allograft kidney cells, thereby reducing their immunogenicity and decreasing the likelihood of immune-mediated rejection. This agent might also reduce cell death associated with increased HLA expression [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Notably, Tacrolimus treatment exhibits a dose-dependent reduction in HLA expression while enhancing cell viability, thereby supporting its role in attenuating alloimmune responses and maintaining graft integrity in kidney transplantation, as demonstrated on our kidney organoid model.</p><p id="Par28">Additionally, we detailed the distribution of various T cell subsets within the allogeneic environment. In scenarios of HLA mismatch between kidney and immune cells in a co-culture setting, immune cell activation might occur via established pathways such as allo-recognition, direct or indirect presentation of allo-antigen, and cytokine release [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. This interaction between activated immune cells and kidney cells can provoke immune-mediated damage to kidney cells, leading to conditions such as allograft rejection [<xref ref-type="bibr" rid="CR27">27</xref>]. This study observed an increase in effector T cells and a decrease in na&#239;ve T cells, consistent with previous findings that graft infiltration by effector T cells can elevated inflammatory cytokine activity, and induce kidney transplant rejection [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. In addition, our findings demonstrated a shift in T helper cell polarization characterized by a relative decrease in Th1 cells and an increase in Th2 and Th17 cells. While Th1 cells are traditionally associated with acute cellular rejection, Th2 responses may contribute to antibody-mediated rejection and chronic graft injury through B cell activation and IgG1/IgE production [<xref ref-type="bibr" rid="CR42">42</xref>]. Th17 cells also have been implicated in both acute and chronic allograft injury by promoting inflammation and fibrosis via IL-17&#8211;mediated pathways. These observations are consistent with previous reports showing that Th17 cell infiltration correlates with the severity of acute T cell&#8211;mediated rejection in renal biopsies and that IL-17 neutralization can prolong graft survival in animal models [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Thus, the noteworthy changes in T cell subsets observed in PBMCs in our in vitro rejection model likely mirrors the graft damage associated with common clinical graft rejection scenarios.</p><p id="Par29">Lastly, we explored whether variations in the co-culture system, such as increased HLA expression and the activation of immune cells, corresponded with alterations in RNA expressions in the kidney organoids. Transcriptomic profiling revealed significant differences in gene expression between syngeneic and allogeneic conditions, particularly highlighting the enrichment of the NF-&#954;B and TNF&#945; signaling pathways.. These pathways are known to play pivotal roles in mediating immune and inflammatory responses during renal allograft rejection [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. The NF-&#954;B pathway is a central regulator of immune activation, promoting transcription of pro-inflammatory cytokines and adhesion molecules, while TNF&#945; signaling contributes to both inflammation and apoptosis [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Therefore, sustained activation of these pathways has been implicated in acute rejection and chronic allograft injury. To experimentally validate the RNA-seq findings, we performed qRT-PCR analysis of representative genes from these pathways. Notably, we observed upregulation of NF-&#954;B and TNF&#945;, along with increased expression of the downstream proinflammatory cytokine IL-6, and decreased expression of I&#954;B&#945;, a key negative regulator of NF-&#954;B signaling [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. These results confirm that the activation of NF-&#954;B and TNF&#945; signaling in the kidney organoids is not only computationally inferred but also experimentally supported.</p><p id="Par30">Although this study has yielded some significant results, it still has several limitations. First, although the co-culture system with kidney organoids and PBMCs provides a controlled environment, it does not capture the complexity of a full organ transplant scenario, which involves additional immune cells, vascular components, and systemic factors found in a living organism. Especially, it is important to consider the developmental state of the kidney organoids used in this study. We utilized organoids differentiated for 21&#160;days, which consistently exhibit nephron-like structures and express key renal markers, enabling interaction with immune cells. However, their immature status may affect the allogeneic immune response by altering antigen presentation or cytokine profiles. Future studies should investigate how organoid maturation influences immune activation in transplant models. Second, tacrolimus was selected as the representative immunosuppressive agent due to its widespread and predominant use in contemporary renal transplantation protocols [<xref ref-type="bibr" rid="CR42">42</xref>]. Nonetheless, further studies investigating the immunological impact of commonly used combination regimens, such as Tacrolimus with mycophenolate mofetil and corticosteroids, will be essential to more fully understand the in vivo relevance of our findings. Third, the focus on T cells and their subsets does not include other critical immune cells involved in transplant rejection, such as B cells, macrophages, and dendritic cells. The limited number of immune cells retrievable in vitro restricted the reliability of analysis for those cells. Detailed characterization of those cells would require a larger-scale experimental system. Future investigations using optimized models or in vivo approaches will be necessary to elucidate the comprehensive immune landscape during renal allograft rejection. Lastly, the generation of kidney organoids from hiPSCs and their subsequent use in co-culture systems require specialized skills and resources. Variability in organoid differentiation and co-culture conditions could impact the reproducibility and scalability of these findings for broader applications. A sophisticated protocol for creating kidney organoids that allows for long-term culture, along with the integration of a microfluidic system to incorporate vascular systems and secondary lymphoid tissues, could address these limitations.</p></sec><sec id="Sec21"><title>Conclusion</title><p id="Par31">In conclusion, our study offers a comprehensive characterization of allogeneic interactions within the kidney organoid co-culture system, providing valuable insights into the pathophysiology of transplant rejection. By identifying key molecular and cellular changes, we establish a foundation for the development of targeted therapeutic interventions that aim to improve transplant outcomes and extend graft survival.</p></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="18_2025_5867_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 1966 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xlink:href="18_2025_5867_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file2 (DOCX 17 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>SWL and BHC designed the study. SC, XF, DHN, YJS, HL carried out experiments. HK, EJO, analyzed and interpreted the data. SWL and BHC drafted the manuscript. BHC supervised the study. All authors approved the final manuscript and agreed to submit this work to this journal.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (RS-2023&#8211;00209312 and NRF-2021R1A2C2005192).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par32">The study was approved the 8th of January, 2020, by Institutional Review Board of Seoul St. Mary&#8217;s Hospital (KC19TISI0901). Title: &#8220;Development of patient tailored kidney disease research platform using kidney organoid system&#8221;. All subjects provided informed consent for inclusion before they participated in this study. This study was conducted in accordance with the Declaration of Helsinki.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par33">All authors confirm their consent for publication.</p></notes><notes id="FPar3"><title>Disclosure of AI</title><p id="Par34">The authors declare that they have not used Artificial Intelligence in this study.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par35">All the authors have declared no competing interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meier-Kriesche</surname><given-names>HU</given-names></name><name name-style="western"><surname>Kaplan</surname><given-names>B</given-names></name></person-group><article-title>Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis</article-title><source>Transplantation</source><year>2002</year><volume>74</volume><fpage>1377</fpage><lpage>1381</lpage><pub-id pub-id-type="pmid">12451234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-200211270-00005</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Meier-Kriesche HU, Kaplan B (2002) Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 74:1377&#8211;1381<pub-id pub-id-type="pmid">12451234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-200211270-00005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>N</given-names></name><name name-style="western"><surname>Okada</surname><given-names>M</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Tsujita</surname><given-names>M</given-names></name><name name-style="western"><surname>Hiramitsu</surname><given-names>T</given-names></name><name name-style="western"><surname>Narumi</surname><given-names>S</given-names></name><name name-style="western"><surname>Katayama</surname><given-names>A</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Uchida</surname><given-names>K</given-names></name><name name-style="western"><surname>Watarai</surname><given-names>Y</given-names></name></person-group><article-title>Association of dialysis duration with outcomes after transplantation in a Japanese cohort</article-title><source>Clin J Am Soc Nephrol</source><year>2016</year><volume>11</volume><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">26728589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.08670815</pub-id><pub-id pub-id-type="pmcid">PMC4791830</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Goto N, Okada M, Yamamoto T, Tsujita M, Hiramitsu T, Narumi S, Katayama A, Kobayashi T, Uchida K, Watarai Y (2016) Association of dialysis duration with outcomes after transplantation in a Japanese cohort. Clin J Am Soc Nephrol 11:497&#8211;504<pub-id pub-id-type="pmid">26728589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.08670815</pub-id><pub-id pub-id-type="pmcid">PMC4791830</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rampersad</surname><given-names>C</given-names></name><name name-style="western"><surname>Balshaw</surname><given-names>R</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>IW</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J</given-names></name><name name-style="western"><surname>Karpinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Birk</surname><given-names>P</given-names></name><name name-style="western"><surname>Rush</surname><given-names>DN</given-names></name><name name-style="western"><surname>Nickerson</surname><given-names>PW</given-names></name><etal/></person-group><article-title>The negative impact of T cell-mediated rejection on renal allograft survival in the modern era</article-title><source>Am J Transplant</source><year>2022</year><volume>22</volume><fpage>761</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">34717048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajt.16883</pub-id><pub-id pub-id-type="pmcid">PMC9299170</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Rampersad C, Balshaw R, Gibson IW, Ho J, Shaw J, Karpinski M, Goldberg A, Birk P, Rush DN, Nickerson PW et al (2022) The negative impact of T cell-mediated rejection on renal allograft survival in the modern era. Am J Transplant 22:761&#8211;771<pub-id pub-id-type="pmid">34717048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajt.16883</pub-id><pub-id pub-id-type="pmcid">PMC9299170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiebe</surname><given-names>C</given-names></name><name name-style="western"><surname>Rush</surname><given-names>DN</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>IW</given-names></name><name name-style="western"><surname>Pochinco</surname><given-names>D</given-names></name><name name-style="western"><surname>Birk</surname><given-names>PE</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Blydt-Hansen</surname><given-names>T</given-names></name><name name-style="western"><surname>Karpinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J</given-names></name><etal/></person-group><article-title>Evidence for the alloimmune basis and prognostic significance of borderline T cell-mediated rejection</article-title><source>Am J Transplant</source><year>2020</year><volume>20</volume><fpage>2499</fpage><lpage>2508</lpage><pub-id pub-id-type="pmid">32185878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajt.15860</pub-id><pub-id pub-id-type="pmcid">PMC7496654</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wiebe C, Rush DN, Gibson IW, Pochinco D, Birk PE, Goldberg A, Blydt-Hansen T, Karpinski M, Shaw J, Ho J et al (2020) Evidence for the alloimmune basis and prognostic significance of borderline T cell-mediated rejection. Am J Transplant 20:2499&#8211;2508<pub-id pub-id-type="pmid">32185878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajt.15860</pub-id><pub-id pub-id-type="pmcid">PMC7496654</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hariharan</surname><given-names>S</given-names></name><name name-style="western"><surname>Israni</surname><given-names>AK</given-names></name><name name-style="western"><surname>Danovitch</surname><given-names>G</given-names></name></person-group><article-title>Long-term survival after kidney transplantation</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>729</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">34407344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra2014530</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Hariharan S, Israni AK, Danovitch G (2021) Long-term survival after kidney transplantation. N Engl J Med 385:729&#8211;743<pub-id pub-id-type="pmid">34407344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra2014530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halloran</surname><given-names>PF</given-names></name></person-group><article-title>Immunosuppressive drugs for kidney transplantation</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2715</fpage><lpage>2729</lpage><pub-id pub-id-type="pmid">15616206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra033540</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351:2715&#8211;2729<pub-id pub-id-type="pmid">15616206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra033540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peelen</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hoogduijn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hesselink</surname><given-names>DA</given-names></name><name name-style="western"><surname>Baan</surname><given-names>CC</given-names></name></person-group><article-title>Advanced in vitro research models to study the role of endothelial cells in solid organ transplantation</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>607953</fpage><pub-id pub-id-type="pmid">33664744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.607953</pub-id><pub-id pub-id-type="pmcid">PMC7921837</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Peelen DM, Hoogduijn MJ, Hesselink DA, Baan CC (2021) Advanced in vitro research models to study the role of endothelial cells in solid organ transplantation. Front Immunol 12:607953<pub-id pub-id-type="pmid">33664744</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.607953</pub-id><pub-id pub-id-type="pmcid">PMC7921837</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wenzel</surname><given-names>N</given-names></name><name name-style="western"><surname>Blasczyk</surname><given-names>R</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>C</given-names></name></person-group><article-title>Animal models in allogenic solid organ transplantation</article-title><source>Transplantology</source><year>2021</year><volume>2</volume><fpage>13</fpage></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wenzel N, Blasczyk R, Figueiredo C (2021) Animal models in allogenic solid organ transplantation. Transplantology 2:13</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>AS</given-names></name><name name-style="western"><surname>Alegre</surname><given-names>ML</given-names></name><name name-style="western"><surname>Miller</surname><given-names>ML</given-names></name><name name-style="western"><surname>Fairchild</surname><given-names>RL</given-names></name></person-group><article-title>Lessons and limits of mouse models</article-title><source>Cold Spring Harb Perspect Med</source><year>2013</year><volume>3</volume><fpage>a015495</fpage><pub-id pub-id-type="pmid">24296351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a015495</pub-id><pub-id pub-id-type="pmcid">PMC3839603</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Chong AS, Alegre ML, Miller ML, Fairchild RL (2013) Lessons and limits of mouse models. Cold Spring Harb Perspect Med 3:a015495<pub-id pub-id-type="pmid">24296351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a015495</pub-id><pub-id pub-id-type="pmcid">PMC3839603</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BM</given-names></name><name name-style="western"><surname>Doh</surname><given-names>KC</given-names></name><name name-style="western"><surname>Cho</surname><given-names>ML</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CW</given-names></name><name name-style="western"><surname>Chung</surname><given-names>BH</given-names></name></person-group><article-title>Clinical significance of CCR7(+)CD8(+) T cells in kidney transplant recipients with allograft rejection</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>8827</fpage><pub-id pub-id-type="pmid">29891963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-27141-6</pub-id><pub-id pub-id-type="pmcid">PMC5995850</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kim KW, Kim BM, Doh KC, Cho ML, Yang CW, Chung BH (2018) Clinical significance of CCR7(+)CD8(+) T cells in kidney transplant recipients with allograft rejection. Sci Rep 8:8827<pub-id pub-id-type="pmid">29891963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-27141-6</pub-id><pub-id pub-id-type="pmcid">PMC5995850</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>BH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BM</given-names></name><name name-style="western"><surname>Doh</surname><given-names>KC</given-names></name><name name-style="western"><surname>Cho</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kim</surname><given-names>KW</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CW</given-names></name></person-group><article-title>Protective effect of 1alpha,25-dihydroxyvitamin D3 on effector CD4+ T cell induced injury in human renal proximal tubular epithelial cells</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0172536</fpage><pub-id pub-id-type="pmid">28245293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0172536</pub-id><pub-id pub-id-type="pmcid">PMC5330482</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Chung BH, Kim BM, Doh KC, Cho ML, Kim KW, Yang CW (2017) Protective effect of 1alpha,25-dihydroxyvitamin D3 on effector CD4+ T cell induced injury in human renal proximal tubular epithelial cells. PLoS One 12:e0172536<pub-id pub-id-type="pmid">28245293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0172536</pub-id><pub-id pub-id-type="pmcid">PMC5330482</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dilmen</surname><given-names>E</given-names></name><name name-style="western"><surname>Orhon</surname><given-names>I</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>J</given-names></name><name name-style="western"><surname>Hoenderop</surname><given-names>JGJ</given-names></name></person-group><article-title>Advancements in kidney organoids and tubuloids to study (dys)function</article-title><source>Trends Cell Biol</source><year>2024</year><volume>34</volume><fpage>299</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">37865608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2023.09.005</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Dilmen E, Orhon I, Jansen J, Hoenderop JGJ (2024) Advancements in kidney organoids and tubuloids to study (dys)function. Trends Cell Biol 34:299&#8211;311<pub-id pub-id-type="pmid">37865608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcb.2023.09.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>BS</given-names></name></person-group><article-title>Modeling kidney disease with iPS cells</article-title><source>Biomark Insights</source><year>2015</year><volume>10</volume><fpage>153</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">26740740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/BMI.S20054</pub-id><pub-id pub-id-type="pmcid">PMC4689367</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Freedman BS (2015) Modeling kidney disease with iPS cells. Biomark Insights 10:153&#8211;169<pub-id pub-id-type="pmid">26740740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4137/BMI.S20054</pub-id><pub-id pub-id-type="pmcid">PMC4689367</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>RG</given-names></name><name name-style="western"><surname>Daley</surname><given-names>GQ</given-names></name></person-group><article-title>Induced pluripotent stem cells in disease modelling and drug discovery</article-title><source>Nat Rev Genet</source><year>2019</year><volume>20</volume><fpage>377</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">30737492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-019-0100-z</pub-id><pub-id pub-id-type="pmcid">PMC6584039</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Rowe RG, Daley GQ (2019) Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet 20:377&#8211;388<pub-id pub-id-type="pmid">30737492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-019-0100-z</pub-id><pub-id pub-id-type="pmcid">PMC6584039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>HY</given-names></name><name name-style="western"><surname>Qian</surname><given-names>ZP</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Xu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Da</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Yu</surname><given-names>FX</given-names></name><name name-style="western"><surname>Zha</surname><given-names>Y</given-names></name></person-group><article-title>Human pluripotent stem cell-derived kidney organoids: current progress and challenges</article-title><source>World J Stem Cells</source><year>2024</year><volume>16</volume><fpage>114</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">38455108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4252/wjsc.v16.i2.114</pub-id><pub-id pub-id-type="pmcid">PMC10915962</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Long HY, Qian ZP, Lan Q, Xu YJ, Da JJ, Yu FX, Zha Y (2024) Human pluripotent stem cell-derived kidney organoids: current progress and challenges. World J Stem Cells 16:114&#8211;125<pub-id pub-id-type="pmid">38455108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4252/wjsc.v16.i2.114</pub-id><pub-id pub-id-type="pmcid">PMC10915962</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chambers</surname><given-names>BE</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>NE</given-names></name><name name-style="western"><surname>Wingert</surname><given-names>RA</given-names></name></person-group><article-title>The &#8220;3Ds&#8221; of growing kidney organoids: advances in nephron development, disease modeling, and drug screening</article-title><source>Cells</source><year>2023</year><volume>12</volume><issue>4</issue><fpage>549</fpage><pub-id pub-id-type="pmid">36831216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12040549</pub-id><pub-id pub-id-type="pmcid">PMC9954122</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chambers BE, Weaver NE, Wingert RA (2023) The &#8220;3Ds&#8221; of growing kidney organoids: advances in nephron development, disease modeling, and drug screening. Cells 12(4):549<pub-id pub-id-type="pmid">36831216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells12040549</pub-id><pub-id pub-id-type="pmcid">PMC9954122</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishinakamura</surname><given-names>R</given-names></name></person-group><article-title>Advances and challenges toward developing kidney organoids for clinical applications</article-title><source>Cell Stem Cell</source><year>2023</year><volume>30</volume><fpage>1017</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">37541208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stem.2023.07.011</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Nishinakamura R (2023) Advances and challenges toward developing kidney organoids for clinical applications. Cell Stem Cell 30:1017&#8211;1027<pub-id pub-id-type="pmid">37541208</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stem.2023.07.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero-Guevara</surname><given-names>R</given-names></name><name name-style="western"><surname>Ioannides</surname><given-names>A</given-names></name><name name-style="western"><surname>Xinaris</surname><given-names>C</given-names></name></person-group><article-title>Kidney organoids as disease models: strengths, weaknesses and perspectives</article-title><source>Front Physiol</source><year>2020</year><volume>11</volume><fpage>563981</fpage><pub-id pub-id-type="pmid">33250772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2020.563981</pub-id><pub-id pub-id-type="pmcid">PMC7672034</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Romero-Guevara R, Ioannides A, Xinaris C (2020) Kidney organoids as disease models: strengths, weaknesses and perspectives. Front Physiol 11:563981<pub-id pub-id-type="pmid">33250772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2020.563981</pub-id><pub-id pub-id-type="pmcid">PMC7672034</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedman</surname><given-names>BS</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>CR</given-names></name><name name-style="western"><surname>Lam</surname><given-names>AQ</given-names></name><name name-style="western"><surname>Fu</surname><given-names>H</given-names></name><name name-style="western"><surname>Morizane</surname><given-names>R</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>V</given-names></name><name name-style="western"><surname>Saad</surname><given-names>AF</given-names></name><name name-style="western"><surname>Li</surname><given-names>MK</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>MR</given-names></name><name name-style="western"><surname>Werff</surname><given-names>RV</given-names></name><etal/></person-group><article-title>Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>8715</fpage><pub-id pub-id-type="pmid">26493500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms9715</pub-id><pub-id pub-id-type="pmcid">PMC4620584</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Freedman BS, Brooks CR, Lam AQ, Fu H, Morizane R, Agrawal V, Saad AF, Li MK, Hughes MR, Werff RV et al (2015) Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun 6:8715<pub-id pub-id-type="pmid">26493500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms9715</pub-id><pub-id pub-id-type="pmcid">PMC4620584</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>SW</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Shin</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Ko</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><name name-style="western"><surname>Chung</surname><given-names>BH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CW</given-names></name></person-group><article-title>CRISPR-Cas9-mediated correction of <italic toggle="yes">SLC12A3</italic> gene mutation rescues the gitelman&#8217;s disease phenotype in a patient-derived kidney organoid system</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>3</issue><fpage>3019</fpage><pub-id pub-id-type="pmid">36769335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24033019</pub-id><pub-id pub-id-type="pmcid">PMC9917614</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lim SW, Fang X, Cui S, Lee H, Shin YJ, Ko EJ, Lee KI, Lee JY, Chung BH, Yang CW (2023) CRISPR-Cas9-mediated correction of <italic toggle="yes">SLC12A3</italic> gene mutation rescues the gitelman&#8217;s disease phenotype in a patient-derived kidney organoid system. Int J Mol Sci 24(3):3019<pub-id pub-id-type="pmid">36769335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms24033019</pub-id><pub-id pub-id-type="pmcid">PMC9917614</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>S</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Shin</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Koh</surname><given-names>ES</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>HS</given-names></name><name name-style="western"><surname>Lim</surname><given-names>SW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system</article-title><source>J Transl Med</source><year>2023</year><volume>21</volume><fpage>138</fpage><pub-id pub-id-type="pmid">36814269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-03992-0</pub-id><pub-id pub-id-type="pmcid">PMC9948377</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Cui S, Fang X, Lee H, Shin YJ, Koh ES, Chung S, Park HS, Lim SW, Lee KI, Lee JY et al (2023) Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system. J Transl Med 21:138<pub-id pub-id-type="pmid">36814269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-023-03992-0</pub-id><pub-id pub-id-type="pmcid">PMC9948377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>S</given-names></name><name name-style="western"><surname>Shin</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H</given-names></name><name name-style="western"><surname>Eum</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ko</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lim</surname><given-names>SW</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KI</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name><etal/></person-group><article-title>CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model</article-title><source>Transl Res</source><year>2023</year><volume>258</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">36805562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2023.02.005</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Cui S, Shin YJ, Fang X, Lee H, Eum SH, Ko EJ, Lim SW, Shin E, Lee KI, Lee JY et al (2023) CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model. Transl Res 258:35&#8211;46<pub-id pub-id-type="pmid">36805562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2023.02.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>NM</given-names></name><name name-style="western"><surname>Song</surname><given-names>X</given-names></name><name name-style="western"><surname>Czerniecki</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gulieva</surname><given-names>RE</given-names></name><name name-style="western"><surname>Churchill</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YK</given-names></name><name name-style="western"><surname>Winston</surname><given-names>K</given-names></name><name name-style="western"><surname>Tran</surname><given-names>LM</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease</article-title><source>Nat Mater</source><year>2017</year><volume>16</volume><fpage>1112</fpage><lpage>1119</lpage><pub-id pub-id-type="pmid">28967916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmat4994</pub-id><pub-id pub-id-type="pmcid">PMC5936694</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Cruz NM, Song X, Czerniecki SM, Gulieva RE, Churchill AJ, Kim YK, Winston K, Tran LM, Diaz MA, Fu H et al (2017) Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease. Nat Mater 16:1112&#8211;1119<pub-id pub-id-type="pmid">28967916</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmat4994</pub-id><pub-id pub-id-type="pmcid">PMC5936694</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langmead</surname><given-names>B</given-names></name><name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nat Methods</source><year>2012</year><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">22388286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmcid">PMC3322381</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Langmead B, Salzberg SL (2012) Fast gapped-read alignment with bowtie 2. Nat Methods 9:357&#8211;359<pub-id pub-id-type="pmid">22388286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmcid">PMC3322381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinlan</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hall</surname><given-names>IM</given-names></name></person-group><article-title>BEDtools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><year>2010</year><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">20110278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmcid">PMC2832824</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Quinlan AR, Hall IM (2010) BEDtools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26:841&#8211;842<pub-id pub-id-type="pmid">20110278</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmcid">PMC2832824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gentleman</surname><given-names>RC</given-names></name><name name-style="western"><surname>Carey</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Bates</surname><given-names>DM</given-names></name><name name-style="western"><surname>Bolstad</surname><given-names>B</given-names></name><name name-style="western"><surname>Dettling</surname><given-names>M</given-names></name><name name-style="western"><surname>Dudoit</surname><given-names>S</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>B</given-names></name><name name-style="western"><surname>Gautier</surname><given-names>L</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gentry</surname><given-names>J</given-names></name><etal/></person-group><article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title><source>Genome Biol</source><year>2004</year><volume>5</volume><fpage>R80</fpage><pub-id pub-id-type="pmid">15461798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2004-5-10-r80</pub-id><pub-id pub-id-type="pmcid">PMC545600</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80<pub-id pub-id-type="pmid">15461798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/gb-2004-5-10-r80</pub-id><pub-id pub-id-type="pmcid">PMC545600</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nankivell</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>SI</given-names></name></person-group><article-title>Rejection of the kidney allograft</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><fpage>1451</fpage><lpage>1462</lpage><pub-id pub-id-type="pmid">20925547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra0902927</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Nankivell BJ, Alexander SI (2010) Rejection of the kidney allograft. N Engl J Med 363:1451&#8211;1462<pub-id pub-id-type="pmid">20925547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra0902927</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>O</given-names></name><name name-style="western"><surname>Lechler</surname><given-names>RI</given-names></name></person-group><article-title>New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance</article-title><source>Curr Opin Immunol</source><year>2004</year><volume>16</volume><fpage>550</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">15341998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2004.07.011</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Jiang S, Herrera O, Lechler RI (2004) New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 16:550&#8211;557<pub-id pub-id-type="pmid">15341998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coi.2004.07.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>H</given-names></name><name name-style="western"><surname>Choi</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Baek</surname><given-names>IC</given-names></name><name name-style="western"><surname>Won</surname><given-names>A</given-names></name><name name-style="western"><surname>Park</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>TG</given-names></name><name name-style="western"><surname>Chung</surname><given-names>YJ</given-names></name></person-group><article-title>A walk through the development of human leukocyte antigen typing: from serologic techniques to next-generation sequencing</article-title><source>Clin Transplant Res</source><year>2024</year><volume>38</volume><fpage>294</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">39658458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4285/ctr.24.0055</pub-id><pub-id pub-id-type="pmcid">PMC11732764</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Choi H, Choi EJ, Kim HJ, Baek IC, Won A, Park SJ, Kim TG, Chung YJ (2024) A walk through the development of human leukocyte antigen typing: from serologic techniques to next-generation sequencing. Clin Transplant Res 38:294&#8211;308<pub-id pub-id-type="pmid">39658458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4285/ctr.24.0055</pub-id><pub-id pub-id-type="pmcid">PMC11732764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>RC</given-names></name><name name-style="western"><surname>Opelz</surname><given-names>G</given-names></name><name name-style="western"><surname>McGarvey</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Weil</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Chakkera</surname><given-names>HA</given-names></name></person-group><article-title>The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors</article-title><source>Transplantation</source><year>2016</year><volume>100</volume><fpage>1094</fpage><lpage>1102</lpage><pub-id pub-id-type="pmid">26901078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000001115</pub-id><pub-id pub-id-type="pmcid">PMC8086563</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Williams RC, Opelz G, McGarvey CJ, Weil EJ, Chakkera HA (2016) The risk of transplant failure with HLA mismatch in first adult kidney allografts from deceased donors. Transplantation 100:1094&#8211;1102<pub-id pub-id-type="pmid">26901078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000001115</pub-id><pub-id pub-id-type="pmcid">PMC8086563</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seliger</surname><given-names>B</given-names></name></person-group><article-title>Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies</article-title><source>HLA</source><year>2016</year><volume>88</volume><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">27659281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tan.12898</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Seliger B (2016) Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. HLA 88:213&#8211;220<pub-id pub-id-type="pmid">27659281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/tan.12898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katikaneni</surname><given-names>DS</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L</given-names></name></person-group><article-title>B cell MHC class II signaling: a story of life and death</article-title><source>Hum Immunol</source><year>2019</year><volume>80</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">29715484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humimm.2018.04.013</pub-id><pub-id pub-id-type="pmcid">PMC6207480</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Katikaneni DS, Jin L (2019) B cell MHC class II signaling: a story of life and death. Hum Immunol 80:37&#8211;43<pub-id pub-id-type="pmid">29715484</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humimm.2018.04.013</pub-id><pub-id pub-id-type="pmcid">PMC6207480</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crux</surname><given-names>NB</given-names></name><name name-style="western"><surname>Elahi</surname><given-names>S</given-names></name></person-group><article-title>Human leukocyte antigen (HLA) and immune regulation: how do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections?</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>832</fpage><pub-id pub-id-type="pmid">28769934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00832</pub-id><pub-id pub-id-type="pmcid">PMC5513977</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Crux NB, Elahi S (2017) Human leukocyte antigen (HLA) and immune regulation: how do classical and non-classical HLA alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections? Front Immunol 8:832<pub-id pub-id-type="pmid">28769934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00832</pub-id><pub-id pub-id-type="pmcid">PMC5513977</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>Risk factors for immune-related adverse events: what have we learned and what lies ahead?</article-title><source>Biomark Res</source><year>2021</year><volume>9</volume><fpage>79</fpage><pub-id pub-id-type="pmid">34732257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-021-00314-8</pub-id><pub-id pub-id-type="pmcid">PMC8565046</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M, Xu Y, Zhao J, Zhong W, Wang M (2021) Risk factors for immune-related adverse events: what have we learned and what lies ahead? Biomark Res 9:79<pub-id pub-id-type="pmid">34732257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40364-021-00314-8</pub-id><pub-id pub-id-type="pmcid">PMC8565046</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>HY</given-names></name><name name-style="western"><surname>Seo</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>D</given-names></name><name name-style="western"><surname>Yun</surname><given-names>WS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HK</given-names></name><name name-style="western"><surname>Huh</surname><given-names>S</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>ES</given-names></name><name name-style="western"><surname>Lim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>JY</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Safety of the reduced fixed dose of mycophenolate mofetil confirmed via therapeutic drug monitoring in de novo kidney transplant recipients</article-title><source>Kidney Res Clin Pract</source><year>2025</year><volume>44</volume><fpage>200</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">39445344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23876/j.krcp.23.274</pub-id><pub-id pub-id-type="pmcid">PMC11838851</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Jung HY, Seo YJ, Hwang D, Yun WS, Kim HK, Huh S, Yoo ES, Lim JH, Choi JY, Park SH et al (2025) Safety of the reduced fixed dose of mycophenolate mofetil confirmed via therapeutic drug monitoring in de novo kidney transplant recipients. Kidney Res Clin Pract 44:200&#8211;209<pub-id pub-id-type="pmid">39445344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23876/j.krcp.23.274</pub-id><pub-id pub-id-type="pmcid">PMC11838851</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>SW</given-names></name><name name-style="western"><surname>Shin</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S</given-names></name><name name-style="western"><surname>Ko</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Chung</surname><given-names>BH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>CW</given-names></name></person-group><article-title>Prediction of diabetes mellitus after kidney transplantation using patient-specific induced pluripotent stem cells</article-title><source>Kidney Res Clin Pract</source><year>2024</year><volume>43</volume><fpage>236</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">37448282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23876/j.krcp.22.251</pub-id><pub-id pub-id-type="pmcid">PMC11016675</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Lim SW, Shin YJ, Cui S, Ko EJ, Chung BH, Yang CW (2024) Prediction of diabetes mellitus after kidney transplantation using patient-specific induced pluripotent stem cells. Kidney Res Clin Pract 43:236&#8211;249<pub-id pub-id-type="pmid">37448282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23876/j.krcp.22.251</pub-id><pub-id pub-id-type="pmcid">PMC11016675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Cai</surname><given-names>M</given-names></name></person-group><article-title>Tacrolimus maintains the balance of neutrophil extracellular traps by inducing DNA methylation of neutrophils to reduce immune rejection</article-title><source>Life (Basel)</source><year>2023</year><volume>13</volume><issue>12</issue><fpage>2253</fpage><pub-id pub-id-type="pmid">38137854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life13122253</pub-id><pub-id pub-id-type="pmcid">PMC10744459</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Xu L, Cai M (2023) Tacrolimus maintains the balance of neutrophil extracellular traps by inducing DNA methylation of neutrophils to reduce immune rejection. Life (Basel) 13(12):2253<pub-id pub-id-type="pmid">38137854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/life13122253</pub-id><pub-id pub-id-type="pmcid">PMC10744459</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamoun</surname><given-names>B</given-names></name><name name-style="western"><surname>Torres</surname><given-names>IB</given-names></name><name name-style="western"><surname>Gabaldon</surname><given-names>A</given-names></name><name name-style="western"><surname>Jouve</surname><given-names>T</given-names></name><name name-style="western"><surname>Meneghini</surname><given-names>M</given-names></name><name name-style="western"><surname>Zuniga</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sellares</surname><given-names>J</given-names></name><name name-style="western"><surname>Perello</surname><given-names>M</given-names></name><name name-style="western"><surname>Seron</surname><given-names>D</given-names></name><name name-style="western"><surname>Bestard</surname><given-names>O</given-names></name><etal/></person-group><article-title>Expression of rejection-associated transcripts in early protocol renal transplant biopsies is associated with tacrolimus exposure and graft outcome</article-title><source>Int J Mol Sci</source><year>2024</year><volume>25</volume><issue>6</issue><fpage>3189</fpage><pub-id pub-id-type="pmid">38542163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25063189</pub-id><pub-id pub-id-type="pmcid">PMC10970018</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Chamoun B, Torres IB, Gabaldon A, Jouve T, Meneghini M, Zuniga JM, Sellares J, Perello M, Seron D, Bestard O et al (2024) Expression of rejection-associated transcripts in early protocol renal transplant biopsies is associated with tacrolimus exposure and graft outcome. Int J Mol Sci 25(6):3189<pub-id pub-id-type="pmid">38542163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms25063189</pub-id><pub-id pub-id-type="pmcid">PMC10970018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merville</surname><given-names>P</given-names></name><name name-style="western"><surname>Pouteil-Noble</surname><given-names>C</given-names></name><name name-style="western"><surname>Wijdenes</surname><given-names>J</given-names></name><name name-style="western"><surname>Potaux</surname><given-names>L</given-names></name><name name-style="western"><surname>Touraine</surname><given-names>JL</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J</given-names></name></person-group><article-title>Cells infiltrating rejected human kidney allografts secrete IFN-gamma, IL-6, and IL-10, and are modulated by IL-2 and IL-4</article-title><source>Transplant Proc</source><year>1993</year><volume>25</volume><fpage>111</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">8438243</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Merville P, Pouteil-Noble C, Wijdenes J, Potaux L, Touraine JL, Banchereau J (1993) Cells infiltrating rejected human kidney allografts secrete IFN-gamma, IL-6, and IL-10, and are modulated by IL-2 and IL-4. Transplant Proc 25:111&#8211;113<pub-id pub-id-type="pmid">8438243</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavlakis</surname><given-names>M</given-names></name><name name-style="western"><surname>Strehlau</surname><given-names>J</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>M</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>M</given-names></name><name name-style="western"><surname>Maslinski</surname><given-names>W</given-names></name><name name-style="western"><surname>Strom</surname><given-names>TB</given-names></name></person-group><article-title>Intragraft IL-15 transcripts are increased in human renal allograft rejection</article-title><source>Transplantation</source><year>1996</year><volume>62</volume><fpage>543</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">8781624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199608270-00020</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB (1996) Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 62:543&#8211;545<pub-id pub-id-type="pmid">8781624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007890-199608270-00020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halloran</surname><given-names>PF</given-names></name></person-group><article-title>T cell-mediated rejection of kidney transplants: a personal viewpoint</article-title><source>Am J Transplant</source><year>2010</year><volume>10</volume><fpage>1126</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">20346061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-6143.2010.03053.x</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Halloran PF (2010) T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transplant 10:1126&#8211;1134<pub-id pub-id-type="pmid">20346061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-6143.2010.03053.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Short</surname><given-names>S</given-names></name><name name-style="western"><surname>Lewik</surname><given-names>G</given-names></name><name name-style="western"><surname>Issa</surname><given-names>F</given-names></name></person-group><article-title>An immune atlas of T cells in transplant rejection: pathways and therapeutic opportunities</article-title><source>Transplantation</source><year>2023</year><volume>107</volume><fpage>2341</fpage><lpage>2352</lpage><pub-id pub-id-type="pmid">37026708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000004572</pub-id><pub-id pub-id-type="pmcid">PMC10593150</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Short S, Lewik G, Issa F (2023) An immune atlas of T cells in transplant rejection: pathways and therapeutic opportunities. Transplantation 107:2341&#8211;2352<pub-id pub-id-type="pmid">37026708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TP.0000000000004572</pub-id><pub-id pub-id-type="pmcid">PMC10593150</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>BH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Piao</surname><given-names>SG</given-names></name><name name-style="western"><surname>Sun</surname><given-names>IO</given-names></name><name name-style="western"><surname>Kang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>SR</given-names></name><name name-style="western"><surname>Park</surname><given-names>HS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>BS</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Higher infiltration by Th17 cells compared with regulatory T cells is associated with severe acute T-cell-mediated graft rejection</article-title><source>Exp Mol Med</source><year>2011</year><volume>43</volume><fpage>630</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">21865860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3858/emm.2011.43.11.071</pub-id><pub-id pub-id-type="pmcid">PMC3249589</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Chung BH, Oh HJ, Piao SG, Sun IO, Kang SH, Choi SR, Park HS, Choi BS, Choi YJ, Park CW et al (2011) Higher infiltration by Th17 cells compared with regulatory T cells is associated with severe acute T-cell-mediated graft rejection. Exp Mol Med 43:630&#8211;637<pub-id pub-id-type="pmid">21865860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3858/emm.2011.43.11.071</pub-id><pub-id pub-id-type="pmcid">PMC3249589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deteix</surname><given-names>C</given-names></name><name name-style="western"><surname>Attuil-Audenis</surname><given-names>V</given-names></name><name name-style="western"><surname>Duthey</surname><given-names>A</given-names></name><name name-style="western"><surname>Patey</surname><given-names>N</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>B</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>V</given-names></name><name name-style="western"><surname>Caligiuri</surname><given-names>G</given-names></name><name name-style="western"><surname>Graff-Dubois</surname><given-names>S</given-names></name><name name-style="western"><surname>Morelon</surname><given-names>E</given-names></name><name name-style="western"><surname>Thaunat</surname><given-names>O</given-names></name></person-group><article-title>Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection</article-title><source>J Immunol</source><year>2010</year><volume>184</volume><fpage>5344</fpage><lpage>5351</lpage><pub-id pub-id-type="pmid">20357253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0902999</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Deteix C, Attuil-Audenis V, Duthey A, Patey N, McGregor B, Dubois V, Caligiuri G, Graff-Dubois S, Morelon E, Thaunat O (2010) Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol 184:5344&#8211;5351<pub-id pub-id-type="pmid">20357253</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0902999</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molinero</surname><given-names>LL</given-names></name><name name-style="western"><surname>Alegre</surname><given-names>ML</given-names></name></person-group><article-title>Role of T cell-nuclear factor kappaB in transplantation</article-title><source>Transplant Rev (Orlando)</source><year>2012</year><volume>26</volume><fpage>189</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">22074783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trre.2011.07.005</pub-id><pub-id pub-id-type="pmcid">PMC3309102</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Molinero LL, Alegre ML (2012) Role of T cell-nuclear factor kappaB in transplantation. Transplant Rev (Orlando) 26:189&#8211;200<pub-id pub-id-type="pmid">22074783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trre.2011.07.005</pub-id><pub-id pub-id-type="pmcid">PMC3309102</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Lamki</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mayadas</surname><given-names>TN</given-names></name></person-group><article-title>TNF receptors: signaling pathways and contribution to renal dysfunction</article-title><source>Kidney Int</source><year>2015</year><volume>87</volume><fpage>281</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">25140911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2014.285</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Al-Lamki RS, Mayadas TN (2015) TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int 87:281&#8211;296<pub-id pub-id-type="pmid">25140911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2014.285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>MA</given-names></name><name name-style="western"><surname>Teixeiro</surname><given-names>E</given-names></name></person-group><article-title>The NF-kappaB signaling network in the life of T cells</article-title><source>Front Immunol</source><year>2025</year><volume>16</volume><fpage>1559494</fpage><pub-id pub-id-type="pmid">40370445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2025.1559494</pub-id><pub-id pub-id-type="pmcid">PMC12075310</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Daniels MA, Teixeiro E (2025) The NF-kappaB signaling network in the life of T cells. Front Immunol 16:1559494<pub-id pub-id-type="pmid">40370445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2025.1559494</pub-id><pub-id pub-id-type="pmcid">PMC12075310</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>D</given-names></name><name name-style="western"><surname>Blaser</surname><given-names>H</given-names></name><name name-style="western"><surname>Mak</surname><given-names>TW</given-names></name></person-group><article-title>Regulation of tumour necrosis factor signalling: live or let die</article-title><source>Nat Rev Immunol</source><year>2015</year><volume>15</volume><fpage>362</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">26008591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3834</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Brenner D, Blaser H, Mak TW (2015) Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 15:362&#8211;374<pub-id pub-id-type="pmid">26008591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri3834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanabe</surname><given-names>K</given-names></name><name name-style="western"><surname>Matsushima-Nishiwaki</surname><given-names>R</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Iida</surname><given-names>H</given-names></name><name name-style="western"><surname>Dohi</surname><given-names>S</given-names></name><name name-style="western"><surname>Kozawa</surname><given-names>O</given-names></name></person-group><article-title>Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells</article-title><source>J Neuroinflammation</source><year>2010</year><volume>7</volume><fpage>16</fpage><pub-id pub-id-type="pmid">20205746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-7-16</pub-id><pub-id pub-id-type="pmcid">PMC2846903</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Tanabe K, Matsushima-Nishiwaki R, Yamaguchi S, Iida H, Dohi S, Kozawa O (2010) Mechanisms of tumor necrosis factor-alpha-induced interleukin-6 synthesis in glioma cells. J Neuroinflammation 7:16<pub-id pub-id-type="pmid">20205746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1742-2094-7-16</pub-id><pub-id pub-id-type="pmcid">PMC2846903</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>A</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Grigoriev</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Park-Min</surname><given-names>KH</given-names></name><name name-style="western"><surname>Park</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ivashkiv</surname><given-names>LB</given-names></name><name name-style="western"><surname>Kalliolias</surname><given-names>GD</given-names></name></person-group><article-title>Tumor necrosis factor alpha induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts</article-title><source>Arthritis Rheum</source><year>2013</year><volume>65</volume><fpage>928</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">23335080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.37853</pub-id><pub-id pub-id-type="pmcid">PMC3618592</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Lee A, Qiao Y, Grigoriev G, Chen J, Park-Min KH, Park SH, Ivashkiv LB, Kalliolias GD (2013) Tumor necrosis factor alpha induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 65:928&#8211;938<pub-id pub-id-type="pmid">23335080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.37853</pub-id><pub-id pub-id-type="pmcid">PMC3618592</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>